408-patient trial fails to demonstrate overall efficacy

Alumis (Alumis, ALMS)'s envudeucitinib (development code ESK-001) is an oral allosteric tyrosine kinase 2 (TYK2) inhibitor with no currently marketed brand. In the global Phase 2b LUMUS trial (NCT05966480), 408 patients with moderate to severe systemic lupus erythematosus (SLE) were randomized into three dose groups and a placebo group. The primary endpoint at week 48, the BILAG-based Combined Lupus Assessment (BICLA), and secondary endpoints were not met. The failure is interpreted as being due more to high placebo responses and biological heterogeneity among patients, rather than a lack of target engagement. The company's stock dropped approximately 55% on the day of the announcement, as the market immediately discounted the asset's value.

IFNGS-high subgroup offers limited development path

In the predefined high interferon gene signature (IFNGS-high) subgroup, strong responses were observed across BICLA, CLASI-50, SRI-4, and low disease activity state (LLDAS). The highest dose group (40mg twice daily) showed the greatest suppression of the interferon pathway, confirming pharmacodynamic target engagement, and no new safety signals were observed. However, the LUMUS trial included fewer IFNGS-high patients than expected, which is a significant portion of moderate to severe SLE, leading to a lower overall response rate. Alumis plans to discuss a biomarker-selected Phase 3 design with regulatory authorities, though this remains at the proposal stage rather than a confirmed Phase 3 entry.

Injectables and TYK2 leaders set competitive benchmarks

Current targeted standard-of-care therapies include GSK's Benlysta (belimumab, BLyS/BAFF inhibitor) and AstraZeneca's Saphnelo (anifrolumab-fnia, IFNAR1 blocker). The FDA approved Benlysta on March 9, 2011, following a 13-2 recommendation from an advisory committee in 2010. Saphnelo was approved on July 30, 2021, without an advisory committee review. Saphnelo's U.S. sales are projected to reach USD 596 million in 2025, demonstrating the commercial potential of SLE-targeted therapies. For envudeucitinib to succeed, it must demonstrate consistent clinical efficacy and evidence of steroid reduction, in addition to the convenience of oral administration, compared to these injectable biologics.

Psoriasis approval remains the core of Alumis' value proposition

The direct oral TYK2 competitor is Bristol-Myers Squibb's Sotyktu (deucravacitinib, TYK2 inhibitor), which is marketed for psoriasis and has two ongoing Phase 3 trials (POETYK SLE-1 and SLE-2) in SLE. Deucravacitinib showed a statistically significant 58.2% SRI-4 response rate at week 32 in the Phase 2 PAISLEY trial, compared to 34.4% with placebo, raising the bar for Alumis' development criteria. Alumis plans to submit an NDA for envudeucitinib for moderate to severe plaque psoriasis to the FDA in Q4 2026, making psoriasis the key to short-term value. Therefore, the lupus Phase 3 remains a high-risk option until a biomarker-selected strategy, regulatory agreement, and reproducible effect size are secured.